Clinical Trial Update: Plasma Biomarker in Predicting Response and Toxicity in HCC Patients Treated With Checkpoint Inhibitors With or Without SBRT

View source ↗

Summary

A completed clinical trial update evaluating plasma biomarkers to predict response and toxicity in hepatocellular carcinoma patients treated with checkpoint inh…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Snippet

Sponsor: The University of Hong Kong | Conditions: Hepatocellular Carcinoma Non-resectable, Stereotactic Body Radiotherapy | Status: COMPLETED